Jco precision oncology.
The actual frequency of NTRK fusions in thyroid cancer is not known, as some targeted exome sequencing can easily miss fusion event involving introns of certain genes. Studies on frequency of NTRK fusions from a single institution and from the TCGA found NTRK fusion in 10 of 451 (2.2%; four NTRK1 and six NTRK3 fusions) and 12 of …Web
DOI: 10.1200/PO.23.00338 JCO Precision Oncology no. 7 (2023) e2300338. Published online December 1, 2023. Published online December 1, 2023. Homologous Recombination Deficiency Across Subtypes of …As significant efforts in distinct geographical areas are underway to enhance the clinical impact of precision oncology, several challenges remain. First, the type of tumor sample used can affect the results of genomic assays and have downstream effects on therapeutic decisions. In a study comparing mutation calls from whole-exome sequencing in ...JCO Precision Oncology ( JCO PO) is a peer-reviewed, online-only journal publishing original research, reports, opinions, and reviews that advance the science and practice of precision oncology and define genomics- and other biomarker-driven clinical care of patients with cancer.DOI: 10.1200/PO.17.00073 JCO Precision Oncology - published online October 3, 2017Oct 31, 2022 · PURPOSE To facilitate implementation of precision medicine in clinical management of cancer, the European Society of Medical Oncology proposed in 2018 a new scale to harmonize and standardize the reporting and interpretation of clinically relevant genomics data (ESMO Scale of Actionability of molecular Targets [ESCAT]). This study aims to characterize the clinical impact of matching targetable ...
journal JCO Precision Oncology is the work of co-first authors Natalie Reizine, MD, a Cancer Center member, and Samantha Socco, PharmD, of @UICPharmacy, …JCO PO publishes controlled randomized clinical trials and other comparative studies in precision oncology. For randomized clinical trials and other comparative studies, authors should carefully follow the ICMJE and CONSORT statement guidelines. To produce consistent results, please refer to JCO PO 's CONSORT template.
This author is a member of the JCO Precision Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript. Employment: Foundation Medicine. …
As significant efforts in distinct geographical areas are underway to enhance the clinical impact of precision oncology, several challenges remain. First, the type of tumor sample used can affect the results of genomic assays and have downstream effects on therapeutic decisions. In a study comparing mutation calls from whole-exome sequencing in ...JCO PO is a peer-reviewed, online-only, article-based journal publishing original research, reports, opinions, and reviews that advance the science and practice of precision oncology and define genomics- and other biomarker-driven clinical care of patients with cancer. Innovative and timely scientific and educational content provide a deeper ...WebSoft boiled eggs are a delicious and versatile dish that can be enjoyed for breakfast, lunch, or dinner. Cooking the perfect soft boiled egg requires precision and attention to detail.As such, scientific outlets in general, and JCO Precision Oncology in particular, owe an immense debt of gratitude to our volunteer peer reviewers. JCO PO strives to provide the highest quality peer review, so in recognition of Peer Review Week 2023 and its theme of Peer Review and The Future of Publishing, ...
DOI: 10.1200/PO.20.00525 JCO Precision Oncology no. 5 (2021) 779-791. Published online May 5, 2021. Prospective Statewide Study of Universal Screening for Hereditary Colorectal Cancer: The Ohio Colorectal Cancer Prevention Initiative Rachel Pearlman, MS 1. x. Rachel Pearlman. Search for articles by this author ...
Nov 12, 2022 · PURPOSE Whether germline multigene panel testing (MGPT) should be performed in all individuals with colorectal cancer (CRC) remains uncertain. Therefore, we aimed to determine the yield and potential clinical impact of MGPT across a large, diverse CRC cohort. METHODS This was a retrospective cohort study of adults with CRC who underwent MGPT of > 10 genes at a commercial laboratory between ...
JCO Precision Oncology showcases high-quality, original documents where all submitted articles are peer reviewed to provide the best quality. The journal welcomes submissions from the research community where emphasis will be placed on the originality and the practical impact of the reported research.Soft boiled eggs are a delicious and versatile dish that can be enjoyed for breakfast, lunch, or dinner. Cooking the perfect soft boiled egg requires precision and attention to detail.DOI: 10.1200/PO.20.00110 JCO Precision Oncology no. 4 (2020) 823-824. Published online July 16, 2020. PMID: 35050756. Remarkable Response to Erdafitinib in Metastatic Lung Adenocarcinoma With FGFR Fusion Samuel A. Urrutia Argueta, MD 1. x. Samuel A. Urrutia Argueta. Search for articles by this author ...Apr 7, 2023 · DOI: 10.1200/PO.22.00509 JCO Precision Oncology no. 7 (2023) e2200509. Published online April 7, 2023. PMID: 37027812 JCO PO recognizes that a practice-changing manuscript may have undergone prior peer review by a highly regarded oncology or cancer research journal, but it was not …DOI: 10.1200/PO.23.00176 JCO Precision Oncology no. 7 (2023) e2300176. Published online December 1, 2023. PMID: 38039430. Utility of Tumor Mutational Burden as a …The increased affordability, accessibility, and reliability of DNA and RNA high-throughput sequencing platforms and bioinformatics capabilities enable oncologists to provide more personalized care, often referred to as precision oncology. 1 However, the accelerated development and diffusion of new commercial and noncommercial tumor …
DOI: 10.1200/PO.22.00675 JCO Precision Oncology no. 7 (2023) e2200675. Published online June 1, 2023. PMID: 37262391. Prevalence and Clinical Implications of Mismatch Repair-Proficient Colorectal Cancer in Patients With Lynch Syndrome Megha Ranganathan, MS 1. x. Megha Ranganathan. Search for articles by this author ...WebAug 14, 2019 · DOI: 10.1200/PO.19.00124 JCO Precision Oncology - published online August 14, 2019 Nov 12, 2022 · PURPOSE Whether germline multigene panel testing (MGPT) should be performed in all individuals with colorectal cancer (CRC) remains uncertain. Therefore, we aimed to determine the yield and potential clinical impact of MGPT across a large, diverse CRC cohort. METHODS This was a retrospective cohort study of adults with CRC who underwent MGPT of > 10 genes at a commercial laboratory between ... DOI: 10.1200/PO.18.00414 JCO Precision Oncology no. 4 (2020) 557-569. Published online June 1, 2020. PMID: 32923885. Intrahepatic Cholangiocarcinoma: Genomic Heterogeneity Between Eastern and Western Patients Jingyu Cao, MD 1. x. Jingyu Cao. Search for articles by this author; Jing ...Although precision oncology is transforming clinical management of patients with cancer, many hospitals face challenges to effectively implement precision oncology. In addition, the cost and time exerted for genomic profiling needs to be balanced with expectations of benefit for each patient. This article summarizes the effort to implement precision oncology in Japan. The most promising ...DOI: 10.1200/PO.20.00037 JCO Precision Oncology no. 4 (2020) 757-766. Published online June 25, 2020. PMID: 35050752. Palbociclib in Patients With Non–Small-Cell Lung Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study Eugene R. Ahn, MD 1. x. Eugene R. Ahn ...Web
DOI: 10.1200/PO.18.00299 JCO Precision Oncology - published online April 25, 2019 PMID: 32914040 Prospective Clinical Validation of the InVisionFirst-Lung Circulating Tumor DNA Assay for Molecular Profiling of Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer
Dec 1, 2023 · PURPOSE Immune checkpoint inhibitors (ICIs) are used for an increasing number of indications across various tumor types, as well as several tumor-agnostic indications in patients with advanced cancer. Although many patients benefit from ICI therapy, others do not, highlighting a need for better predictive biomarkers. Tumor mutational burden (TMB) reflects the global number of mutations within ... As such, scientific outlets in general, and JCO Precision Oncology in particular, owe an immense debt of gratitude to our volunteer peer reviewers. JCO PO strives to provide the highest quality peer review, so in recognition of Peer Review Week 2023 and its theme of Peer Review and The Future of Publishing, ...JCO PO recognizes that a practice-changing manuscript may have undergone prior peer review by a highly regarded oncology or cancer research journal, but it was not …DOI: 10.1200/PO.23.00176 JCO Precision Oncology no. 7 (2023) e2300176. Published online December 1, 2023. PMID: 38039430. Utility of Tumor Mutational Burden as a …Manuscripts Involving Precision Oncology. JCO appreciates the potential value of studies addressing the role of precision oncology in selecting optimal therapy for patients with cancer. Many such studies have already been published, showing the feasibility of performing large scale molecular testing such as Next Generation …DOI: 10.1200/PO.19.00388 JCO Precision Oncology no. 4 (2020) 882-897. Published online July 28, 2020. PMID: 35050761. Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial Clare Gilson, MRCP, MD 1. x. Clare Gilson. Search for …WebPURPOSE With the introduction of precision medicine, treatment options for non–small-cell lung cancer have improved dramatically; however, underutilization, especially in disadvantaged patients, like those living in rural Appalachian regions, is associated with poorer survival. Molecular tumor boards (MTBs) represent a strategy to increase precision medicine use. UK HealthCare at the ...Jul 6, 2023 · Pancreatic cancer remains one of the leading causes of cancer-related death, with an estimated 64,050 new cases and 50,550 deaths in the United States in 2023. 1 Among various malignancies, pancreatic cancer is considered highly aggressive and exhibits one of the lowest 5-year survival rates at 10%. 1 Pancreatic ductal adenocarcinoma (PDAC) accounts for approximately 90% of cases of pancreatic ... DOI: 10.1200/PO.20.00241 JCO Precision Oncology no. 5 (2021) 93-102. Published online January 11, 2021. PMID: 34994593. Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non–Small-Cell Lung Cancer ...DOI: 10.1200/PO.21.00383 JCO Precision Oncology no. 6 (2022) e2100383. Published online February 21, 2022. Published online February 21, 2022. Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA SubstudyWeb
DOI: 10.1200/PO.19.00154 JCO Precision Oncology no. 4 (2020) 6-19. Published online January 7, 2020. PMID: 35050726. International Harmonization of Provisional Diagnostic Criteria for ...
This author is a member of the JCO Precision Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript. Stock and Other Ownership Interests: MolecularMatch, Lutris, Iylon, Frontier Medicines.Web
Apr 7, 2023 · DOI: 10.1200/PO.22.00509 JCO Precision Oncology no. 7 (2023) e2200509. Published online April 7, 2023. PMID: 37027812 22 Aug 2023 ... Veracyte Announces that Findings Published in JCO Precision Oncology Suggest Potential of Decipher GRID-Derived Gene Signatures to Predict ...DOI: 10.1200/PO.19.00115 JCO Precision Oncology - published online October 23, 2019DOI: 10.1200/PO.19.00154 JCO Precision Oncology no. 4 (2020) 6-19. Published online January 7, 2020. PMID: 35050726. International Harmonization of Provisional Diagnostic Criteria for ...DOI: 10.1200/PO.20.00110 JCO Precision Oncology no. 4 (2020) 823-824. Published online July 16, 2020. PMID: 35050756. Remarkable Response to Erdafitinib in Metastatic Lung Adenocarcinoma With FGFR Fusion Samuel A. Urrutia Argueta, MD 1. x. Samuel A. Urrutia Argueta. Search for articles by this author ...Jan 6, 2022 · DOI: 10.1200/PO.21.00002 JCO Precision Oncology no. 6 (2022) e2100002. Published online January 6, 2022. PMID: 35005994 Purpose Appendiceal neoplasms are heterogeneous and are often treated with chemotherapy similarly to colorectal cancer (CRC). Genomic profiling was performed on 703 appendiceal cancer specimens to compare the mutation profiles of appendiceal subtypes to CRC and other cancers, with the ultimate aim to identify potential biomarkers …DOI: 10.1200/PO.20.00178 JCO Precision Oncology no. 5 (2021) 44-50. Published online January 8, 2021. Published online January 8, 2021. Noninvasive Detection of Polyclonal Acquired Resistance to FGFR Inhibition in Patients With Cholangiocarcinoma Harboring FGFR2 AlterationsWebFrom Race-Based to Precision Oncology: Leveraging Behavioral Economics and the Electronic Health Record to Advance Health Equity in Cancer Care Lau-Min et al. Published online: February 17, 2021Acknowledgment of Reviewers, 2023. Peer review is at the core of scientific progress. It is through the careful critique of peer reviewers that manuscripts are scrutinized, evaluated, and improved. An article that has been peer reviewed is determined to be valid and worthy of publication. These peer-reviewed manuscripts are a critical component ...JCO PO publishes controlled randomized clinical trials and other comparative studies in precision oncology. For randomized clinical trials and other comparative studies, authors should carefully follow the ICMJE and CONSORT statement guidelines. To produce consistent results, please refer to JCO PO 's CONSORT template.
JCO PO is a peerreviewed onlineonly articlebased journal publishing original research reports opinions and reviews that advance the science and practice of precision oncology and define genomics and other biomarkerdriven clinical care of patients with cancer. Innovative and timely scientific and educational content provide a deeper ... Stage 4 is the final stage of most cancers that have spread to other areas of the body, states the American Society of Clinical Oncology. Cancer stages are usually determined by the size, growth and spread of the cancer.DOI: 10.1200/PO.19.00172 JCO Precision Oncology - published online September 20, 2019 PMID: 32923866. Venetoclax and Bortezomib in Relapsed/Refractory Early T-Cell Precursor Acute Lymphoblastic Leukemia Roberta La Starza, MD, PhD 1. x. Roberta La Starza. Search for articles by this author ...Instagram:https://instagram. wtai stockaapl.earnings datestock market ai softwareplanet fitness ripoff The Precision Oncology Decision Support system (PODS) was established at The University of Texas MD Anderson Cancer Center in recognition of these needs. 9 Herein, we report our experience with large-scale, institution-wide decision support and its initial clinical utility. These data are among the first to suggest that providing alteration ...This confidence in precision oncology in the absence of definitive RCTs has resulted in creative RWE solutions to the marketplace demand (eg, TAPUR [Targeted Agent and Profiling Utilization Registry] … best discount stock brokerd z z Jun 25, 2020 · PURPOSE The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a phase II pragmatic basket trial evaluating antitumor activity of commercially available targeted agents in patients with advanced cancer with genomic alterations known to be drug targets. Results in a cohort of patients with non–small-cell lung cancer (NSCLC) with CDKN2A alterations treated with palbociclib are ... DOI: 10.1200/PO.20.00069 JCO Precision Oncology no. 4 (2020) 665-679. Published online June 16, 2020. Published online June 16, 2020. BRCA Mutations, Homologous DNA Repair Deficiency, Tumor Mutational Burden, and Response to Immune Checkpoint Inhibition in Recurrent Ovarian Cancer 2024 president betting odds PURPOSE To facilitate implementation of precision medicine in clinical management of cancer, the European Society of Medical Oncology proposed in 2018 a new scale to harmonize and standardize the reporting and interpretation of clinically relevant genomics data (ESMO Scale of Actionability of molecular Targets [ESCAT]). This study aims to characterize the clinical impact of matching targetable ...Oct 6, 2022 · DOI: 10.1200/PO.22.00024 JCO Precision Oncology no. 6 (2022) e2200024. Published online October 6, 2022. PMID: 36201714 DOI: 10.1200/PO.17.00073 JCO Precision Oncology - published online October 3, 2017Web